<DOC>
	<DOCNO>NCT00877929</DOCNO>
	<brief_summary>To demonstrate fix dose combination telmisartan amlodipine effective lower blood pressure .</brief_summary>
	<brief_title>Telmisartan Fixed Dose Combination v Amlodipine Hypertensive Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion : 1 . Hypertension define mean inclinic seat cuff Systolic Blood Pressure &gt; 150 mmHg Visit 3 ( Randomisation visit ) 2 . Diagnosis Type 2 diabetes mellitus 3 . =18 year age date signing inform consent 4 . Ability stop current antihypertensive therapy without unacceptable risk patient ( investigator 's discretion ) 5 . Ability provide write informed consent Exclusion criterion : 1 . Premenopausal woman ( last menstruation &lt; =1 year prior start runin period ) : 1. surgically sterile ; and/or 2. nursing pregnant , 3. childbearing potential NOT practice acceptable mean birth control NOT plan continue practise acceptable method throughout study . The acceptable method birth control : Intrauterine device ( IUD ) ; Oral contraceptive ( start least three month prior start runin period ) Implantable injectable contraceptive Estrogen patch 2 . Night shift worker routinely sleep daytime whose work hour include midnight 4:00 a.m. 3 . Known suspected secondary hypertension ( e.g. , renal artery stenosis , phaeochromocytoma ) 4 . Mean seat Systolic Blood Pressure ( SBP ) =180 mm Hg and/or mean seat Diastolic Blood Pressure ( DBP ) =110 mm Hg visit screen placebo runin period 5 . Patients Type 1 diabetes mellitus 6 . Renal dysfunction define follow laboratory parameter : Serum creatinine &gt; 3.0 mg/dL ( &gt; 265 Âµmol /L ) know creatinine clearance &lt; 30 mL/min clinical marker severe renal impairment 7 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , postrenal transplant patient patient one kidney 8 . Clinically relevant hypokalaemia hyperkalaemia 9 . Uncorrected sodium volume depletion 10 . Primary aldosteronism 11 . Hereditary fructose intolerance 12 . Biliary obstructive disorder ( e.g. , cholestatis ) hepatic insufficiency 13 . Congestive heart failure New York Heart Academy ( NYHA ) functional class CHF IIIIV ( Refer Appendix 10.3 ) 14 . Contraindication placebo runin period ( e.g. , stroke within past six month , myocardial infarction , cardiac surgery , percutaneous transluminal coronary angioplasty , unstable angina coronary artery bypass graft within past three month prior start runin period ) 15 . Clinically significant ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine Investigator 16 . Hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve 17 . Patients whose diabetes stable control least past three month define HbA1C &gt; 10 % 18 . Patients previously experience symptom characteristic angioedema treatment Angiotensin Converting Enzyme ( ACE ) inhibitor angiotensinII receptor antagonist 19 . History drug alcohol dependency within six month prior sign inform consent form 20 . Concomitant administration medication know affect blood pressure , except medication allow protocol 21 . Any investigational drug therapy within one month signing inform consent 22 . Known hypersensitivity component study drug ( telmisartan , amlodipine , placebo ) 23 . History noncompliance inability comply prescribed medication protocol procedures 24 . Any clinical condition , opinion investigator , would allow safe completion protocol safe administration telmisartan amlodipine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>